Anti-murine Il1rl1 T-BsAbs ± IL-15 superagonist reduces leukemia blasts, LSCs and reverses tumor microenvironment-mediated immune tolerance to extend survival in immunocompetent models of AML. Here, IL15 is linked to acute myeloid leukemia.